Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 16 of 16 for “"Palbociclib"”.
-
Combined Inhibition of Ddr1 and Cdk4/6 Induces Synergistic Effects In Er-Positive, Her2-Negative Breast Cancer With Pik3Ca/Akt1 Mutations
… kinase (CDK4/6) inhibitors such as palbociclib in combination with endocrine therapy. Although this is a very effective regimen, disease progression ultimately occurs in most patients. Further, the modulators of palbociclib sensitivity remain unclear. The purpose of this study was to …
-
Targeting Autophagy to Improve Efficacy of Cdk4/6 Inhibition In Breast Cancer
… has led to the development and FDA approval (palbociclib, ribociclib) of CDK4/6 inhibitors for the treatment of advanced estrogen receptor positive breast cancer. However, three major clinical challenges remain: i) adverse events leading to discontinuation of therapy and ii) lack of reliable …
-
Mathematical Modeling of Therapies for MCF7 Breast Cancer Cells
… Further, we show that we can add a new drug, palbociclib, to the model by measuring only two key proteins, c-Myc and hyperphosphorylated RB1, and adjusting only parameters associated with the drug. The model is then able to predict the combination treatment of estrogen deprivation and …
-
Συστηματική ανασκόπηση της αποτελεσματικότητας και της ασφάλειας του Giredestrant στη θεραπεία του καρκίνου του μαστού - Systematic review on the efficacy and safety of Giredestrant for breast cancer therapy
… μελέτη coopERA BC, ο συνδυασμός giredestrant + palbociclib πέτυχε μεγαλύτερη καταστολή του Ki-67 και υψηλότερα ποσοστά πλήρους κυτταρικής παύσης έναντι του anastrozole + palbociclib. Η μελέτη φάσης III evERA BC έδειξε σημαντική βελτίωση της επιβίωσης χωρίς εξέλιξη νόσου με giredestrant + …
-
Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors In Breast Cancer
… cancer cells respond to dinaciclib but not palbociclib. Taken together, this study suggests that targeting CDK2 by inhibitors such as dinaciclib in combination with AIs is a potential therapeutic strategy for HR+ postmenopausal breast cancer patients with LMW-E expressing tumors.</p>
-
Mechanisms of medulloblastoma vulnerability and new targeted therapies
… as a promising and more effective alternative to palbociclib, a CDK4/6 inhibitor currently pursued in clinical studies. We present evidence supporting dinaciclib’s ability to inhibit MB proliferation, impair cancer stemness and induce apoptosis at considerably lower doses than palbociclib. …
-
Does inappropriate DNA replication provide a mechanism for the de novo acquisition of drug resistance?
… Notably, combining Osimertinib with either Palbociclib (a CDK4/6 inhibitor) or AZD1390 (an ATM inhibitor) enhanced cell killing beyond single-agent Osimertinib, with only the Palbociclib combination reducing the replicative fraction of DTP cells. I then explored the fate of DTP cells. …
-
Dissecting the molecular mechanisms of therapeutic resistance in cancer
… activated EGFR signaling upon treatment with palbociclib whereas the GBM22 and MPNST3 models activated SFKs and PDGFRa signaling in resistant tumors. Across all three PDX tumor models, treatment with combination therapies, consisting of palbociclib and an inhibitor targeting the activated …
-
A CELL CYCLE CLOCK REGULATES THE EPIGENETIC LANDSCAPE OF AML CELLS AND DETERMINES SENSITIVITY TO LSD1 INHIBITION
… clinically approved CDK inhibitors, such as Palbociclib, with LSD1 inhibitors. Moreover, the study investigates mechanistically the implications of cell cycle manipulation, focusing on modifications of the epigenome. Our ATAC-seq investigations show that extension of the G1 phase alters …
-
Physicochemical and computational approaches for the prediction of the manufacturability of active pharmaceutical ingredients
… and surface energy of two further APIs, palbociclib and crizotinib, are reported. In general, particles with regular shapes exhibit higher surface energies and a greater propensity to stick. The specific surface energy measured experimentally and total surface energy measured …
-
Mapping the cell cycle-dependent centrosomal interactome
… method based on the CDK4/6 inhibitor palbociclib. Differential analysis of the centrosome interactome resulted in the identification of proteins associated with numerous biological processes, including gene expression, DNA/RNA processing, and cell cycle regulation. Functional analysis …
-
A SEARCH FOR EPIGENETIC VULNERABILITIES OF AML CELLS PERFORMED BY A CDK INHIBITOR¿BASED CRISPR SCREENING
… studies (ongoing) revealed that Palbociclib treatment rewires kinase signaling in the nucleus and chromatin-associated phosphorylation networks, setting the ground for the discovery of mechanistic insights into how cell cycle modulation primes AML cells for epigenetic …
-
Simultaneous Targeting of CDK4/6 and BETs is Independent of RB Status in Osteosarcoma
… pointing to CDK4/6 inhibitors (CDK4/6i), like palbociclib and abemaciclib, as promising therapeutic strategies. However, monotherapy often fails, highlighting the need for effective combination approaches. While functional RB has traditionally been viewed as necessary for CDK4/6i sensitivity, …
-
Impact of Cyclin-Dependent Kinase 4 and 6 Inhibitors on Chemotherapy Utilization and Overall Survival in Women with HR+/HER2– Metastatic Breast Cancer in the United States
Purpose: Delaying chemotherapy remains a vital goal in therapeutic management of HR+/HER2– metastatic breast cancer (MBC). However, recent reports continue to highlight substantially high chemotherapy utilization in earlier therapy lines. In this study, we explored the impact of cyclin-dependent …
-
The Use of Oncology Electronic Health Record Databases to Assess the Effectiveness of Breast Cancer Treatment
… the rate of time-to-next-treatment (TTNT) in palbociclib-letrozole users versus letrozole-only users. TTNT was chosen as an endpoint because it was well-observed in the EHR database and appeared to serve as a meaningful surrogate for treatment effectiveness in the PALOMA-2 trial. All …